CONTEMPORARY APPROACHES TO THE TREATMENT OF ULCERATIVE COLITIS AND CROHN’S DISEASE

Authors

  • Mohamed Mostafa International students faculty, Asia International University, Bukhara Author

Keywords:

Keywords: ulcerative colitis, inflammatory bowel disease, Crohn disease, therapeutics.

Abstract

Abstract: Inflammatory bowel disease (IBD) has emerged as a global health challenge and continues to attract significant research interest. Ongoing investigations have deepened the understanding of disease pathophysiology and have facilitated the development of novel therapeutic strategies. This review examines both conventional and emerging treatment modalities, highlighting their clinical utility, limitations, and future prospects.

References

1.Hanauer, S. B. (2004). Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases, 10(Suppl 1), S3–S9.

2.Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018). ACG clinical guideline: Management of Crohn’s disease in adults. American Journal of Gastroenterology, 113(4), 481–517.

3.Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG clinical guideline: Ulcerative colitis in adults. American Journal of Gastroenterology, 114(3), 384–413.

4.Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., ... & Colombel, J. F. (2005). Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 353(23), 2462–2476.

5.Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., ... & Panés, J. (2017). Tofacitinib as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 376(18), 1723–1736.

6.Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., ... & Borody, T. J. (2017). Multidonor intensive fecal microbiota transplantation for active ulcerative colitis: A randomized controlled trial. JAMA, 318(14), 1200–1210.

7.Imhann, F., Vich Vila, A., Bonder, M. J., Fu, J., Gevers, D., Visschedijk, M. C., ... & Weersma, R. K. (2018). Interplay of host genetics and gut microbiota in Crohn’s disease and ulcerative colitis. Nature Genetics, 50(4), 493–504.

8.Hawkey, C. J., Allez, M., Clark, M. M., Labopin, M., Lindsay, J. O., Ricart, E., ... & Lindsay, J. (2015). Autologous stem cell transplantation for refractory Crohn’s disease: A randomized controlled trial. JAMA, 314(23), 2524–2534.

9.Forbes, G. M., & Thomas, S. (2015). Fecal microbiota transplantation for inflammatory bowel disease: A review of the literature. Journal of Gastroenterology and Hepatology, 30(1), 36–41.

10.Lamprecht, A., Schäfer, U., & Lehr, C. M. (2001). Sizedependent bioadhesion of micro and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceutical Research, 18(6), 788–793.

11.Vyas, S. P., & Sihorkar, V. (2000). Potential of micro and nanocarriers in targeting inflamed colonic mucosa. Advanced Drug Delivery Reviews, 42(1–2), 129–152.

Downloads

Published

2026-06-07